Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie om de veiligheid op lange termijn te evalueren van inclacumab toegediend aan deelnemers met sikkelcelziekte

29 oktober 2026 bijgewerkt door: Pfizer

Een open-label extensieonderzoek om de veiligheid op lange termijn te evalueren van Inclacumab toegediend aan deelnemers met sikkelcelziekte die hebben deelgenomen aan een klinisch onderzoek naar Inclacumab

This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.

Studie Overzicht

Gedetailleerde beschrijving

The study will include approximately 520 adult and adolescent participants (≥ 12 years of age) with SCD.

All participants will receive inclacumab 30 mg/kg administered intravenously every 12 weeks.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

241

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Rio de Janeiro, Brazilië, 20211-030
        • Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO
      • São Paulo, Brazilië, 08270-070
        • Casa de Saude Santa Marcelina
      • São Paulo, Brazilië, 01232-010
        • Hospital Samaritano Higienópolis/Esho Empresa De Servicos Hospitalares S.A
      • São Paulo, Brazilië, 08270-120
        • CEPEC-Centro de Pesquisa Clinica
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brazilië, 41253-190
        • Instituto D'Or de Pesquisa e Ensino - Hospital São Rafael
    • Pernambuco
      • Recife, Pernambuco, Brazilië, 50070-460
        • Multihemo Servicos Medicos S/A
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazilië, 90035-903
        • Hospital de Clínicas de Porto Alegre
    • São Paulo
      • Ribeirão Preto, São Paulo, Brazilië, 14051-140
        • Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
      • São José do Rio Preto, São Paulo, Brazilië, 15090-000
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto
    • Atlántico
      • Barranquilla, Atlántico, Colombia, 080020
        • Clinica de la Costa Ltda.
    • Cesar Department
      • Valledupar, Cesar Department, Colombia, 200001
        • Sociedad de Oncología y hematología del Cesar
      • Eldoret, Kenia, 30100
        • International Cancer Institute
      • Nairobi, Kenia, 00100
        • Gertrude's Children's Hospital
      • Nairobi, Kenia, 00100
        • Kenya Medical Research Institute - Centre for Respiratory Disease Research
      • Nairobi, Kenia, 00200
        • Strathmore University CREATES
    • Siaya County
      • Kisumu, Siaya County, Kenia, 40600
        • KEMRI/CRDR Siaya Clinical Research Annex
    • Beirut
      • Hamra, Beirut, Libanon
        • American University of Beirut Medical Center
    • North Lebanon
      • Tripoli, North Lebanon, Libanon
        • Nini Hospital
      • Enugu, Niger, 460000
        • University of Nigeria Teaching Hospital
      • Kaduna, Niger, 800212
        • Barau Dikko Teaching Hospital/Kaduna State University
      • Kano, Niger, 700223
        • Aminu Kano Teaching Hospital
      • Lagos, Niger, 100254
        • Department of Pediatrics, College of Medicine, Lagos University Teaching Hospital
    • Cross River State
      • Calabar, Cross River State, Niger, 540242
        • University of Calabar Teaching Hospital
    • Federal Capital Territory
      • Abuja, Federal Capital Territory, Niger, 900211
        • National Hospital Abuja
      • Gwagwalada, Federal Capital Territory, Niger, 902101
        • University of Abuja Teaching Hospital
    • Kaduna State
      • Zaria, Kaduna State, Niger, 810105
        • Ahmadu Bello University Teaching Hospital
      • Muscat, Oman, 123
        • Sultan Qaboos University Hospital
    • Southern
      • Jizan, Southern, Saoedi-Arabië, 82943
        • Prince Mohammed bin Nasser Hospital
      • Dar es Salaam, Tanzania, 11101
        • National Institute for Medical Research (NIMR)
      • Adana, Turkije (Türkiye), 01130
        • Acibadem Adana Hastanesi Cocuk Hematoloji Onkoloji
      • Adana, Turkije (Türkiye), 01250
        • Baskent University Adana Appl. and Research Central, Yuregir Baskent Hospital Hematology
      • Ankara, Turkije (Türkiye), 06430
        • Hacettepe University Ihsan Dogramaci Children Hospital
    • Alabama
      • Mobile, Alabama, Verenigde Staten, 36604
        • University of South Alabama Children's and Women's Hospital
      • Mobile, Alabama, Verenigde Staten, 36604
        • Strada Patient Care Center, Pediatric Hematology
      • Mobile, Alabama, Verenigde Staten, 36606
        • South Alabama Medical Science Foundation
    • Arkansas
      • Little Rock, Arkansas, Verenigde Staten, 72202
        • Arkansas Children's Hospital
    • California
      • Orange, California, Verenigde Staten, 92868
        • UC Irvine Medical Center
    • Connecticut
      • Farmington, Connecticut, Verenigde Staten, 06030
        • UConn-Neag Comprehensive Cancer Center
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60612
        • University of Illinois Hospital and Health Sciences System (UI Health)
      • Chicago, Illinois, Verenigde Staten, 60612
        • University of Illinois at Chicago (UIC) Clinical Research Center
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02215
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, Verenigde Staten, 02215
        • Dana-Farber Cancer Institute IDS Pharmacy
      • Boston, Massachusetts, Verenigde Staten, 02115
        • Brigham And Woman's Hospital
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109
        • University of Michigan Hospitals - Michigan Medicine
    • New York
      • The Bronx, New York, Verenigde Staten, 10461
        • Jacobi Medical Center
    • North Carolina
      • Durham, North Carolina, Verenigde Staten, 27705
        • Duke University Medical Center
      • Durham, North Carolina, Verenigde Staten, 27710
        • DUMC Investigational Drug Services Pharmacy
    • Texas
      • Houston, Texas, Verenigde Staten, 77030
        • McGovern Medical School at UTHealth
      • Houston, Texas, Verenigde Staten, 77030
        • UT Physicians Comprehensive Sickle Cell Center Houston
      • Houston, Texas, Verenigde Staten, 77030
        • UT Health Science Center at Houston - Clinical Research Unit at Memorial Hermann Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

12 jaar en ouder (Kind, Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

Participants who meet all the following criteria will be eligible for study enrollment:

  1. Male or female participant with SCD who participated and received study drug in a GBT-Sponsored inclacumab clinical study.

  2. Participant has completed the originating inclacumab study within 30 calendar days of the Day 1 Visit. Participants who discontinued study drug in the originating study due to a non-study drug-related AE, but who remained on study, may be eligible for treatment in this study provided the AE does not pose a risk for treatment with inclacumab.

  3. Female participants of childbearing potential are required to have a negative urine pregnancy test prior to dosing on Day 1.

    Note: Female participants who become of childbearing potential during the study must be willing to have a negative urine pregnancy test to remain in the study.

  4. If sexually active, female participants of childbearing potential must consistently use highly effective methods of contraception consistently throughout the study and for at least 165 days after the last dose of study drug. If sexually active, male participants must use barrier methods of contraception until 165 days after the last dose of study drug.

  5. Participant has provided written informed consent/assent. For underage participants, both the consent of the participant's legal representative or legal guardian and the participant's assent (where applicable) must be obtained based on local requirement.

Exclusion Criteria:

Participants meeting any of the following exclusion criteria will not be eligible for study enrollment:

  1. Female participant who is breastfeeding or pregnant.
  2. Participant had an infusions-related reaction (IRR) in the originating inclacumab clinical study.
  3. Participant withdrew consent from the originating inclacumab clinical study.
  4. Participant was lost to follow-up from the originating inclacumab clinical study.
  5. Participant has any medical, psychological, safety, or behavioral conditions that, in the opinion of the Investigator, may confound safety interpretation, interfere with compliance, or preclude informed consent.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Inclacumab 30 mg/kg

Inclacumab 30 mg/kg administered intravenously (IV)

Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Tijdsspanne: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A TEAE was defined as an AE with an onset after the initiation of dosing for the first dose of study drug in current study GBT2104-133 (NCT05348915). TEAEs included both serious and all other AEs.

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Annualized Rate of Vaso-occlusive Crises (VOCs)
Tijdsspanne: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC = (total number of VOC events)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication
Tijdsspanne: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC that required admission to a healthcare facility and treatment with parenteral pain medication was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in admission to a healthcare facility; 3) required parenteral narcotic agents or parenteral NSAIDs. Admission to a healthcare facility included: 1) a hospital admission or 2) an admission to an emergency room, observation unit, or infusion center for >= 12 hours or 3) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. Annualized rate of VOC = (total number of VOC events)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Number of Inpatient Hospitalization Days for a VOC
Tijdsspanne: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Annualized rate of hospitalization days = (total number of hospitalization days)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of SCD-related Urgent Care Visits
Tijdsspanne: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Urgent care visits included visits to the clinic, emergency room, and hospital. Analysis of this outcome measure included both VOC and non-VOC SCD-related events. Annualized rate of visits = (total number of visits)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks
Tijdsspanne: From first dose of study treatment (Day 1) up to Week 48

The percentage of total days missed from school or work due to SCD pain symptoms out of the total expected days of school or work attendance for the first 48 weeks of the study is presented in this outcome measure.

From first dose of study treatment (Day 1) up to Week 48
Annualized Rate of Complicated VOCs
Tijdsspanne: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Complicated VOCs included acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism. Annualized VOC rate = (total number of VOC events)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of Red Blood Cell (RBC) Transfusions
Tijdsspanne: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Annualized RBC transfusion rate = (total number of RBC transfusions)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: Pfizer CT.gov Call Center, Pfizer

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

29 maart 2022

Primaire voltooiing (Werkelijk)

7 november 2025

Studie voltooiing (Werkelijk)

7 november 2025

Studieregistratiedata

Eerst ingediend

29 maart 2022

Eerst ingediend dat voldeed aan de QC-criteria

21 april 2022

Eerst geplaatst (Werkelijk)

27 april 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 november 2026

Laatste update ingediend die voldeed aan QC-criteria

29 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren